Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (2,455)	$ (3,028)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sales of in process research and development	(144)	(2,139)
Stock-based compensation expense	397	1,722
Changes in operating assets and liabilities:
Prepaid expenses and other assets	2,192	764
Accounts payable, accrued expenses and other	(208)	(1,944)
Net cash used in operating activities	(218)	(4,625)
Cash flows from investing activities
Proceeds from sale of in-process research and development assets	144	2,139
Net cash provided by investing activities	144	2,139
Cash flows from financing activities
Proceeds from exercise of options	239
Repayment of other liability		(56)
Net cash provided by (used in) financing activities	239	(56)
Net increase (decrease) in cash and cash equivalents	165	(2,542)
Cash and cash equivalents, beginning of period	14,038	16,580
Cash and cash equivalents, end of period	$ 14,203	$ 14,038